EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

Sources

Dose Diligence research deskSection 04 · Page 17 of 17Last updated 17 Nov 2026

Federal compounding law, policy and litigation

Quality, state standards and traceability

Approvals, coverage, safety and telehealth enforcement

Sources cited on this page

  1. uscode.house.gov · Source 1 ↗https://uscode.house.gov/us/usc/119-120/t21/s353a/
  2. uscode.house.gov · Source 2 ↗https://uscode.house.gov/us/usc/119-136/t21/s353b/
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  4. fda.gov · Source 4 ↗https://www.fda.gov/media/184606/download?attachment=
  5. fda.gov · Source 5 ↗https://www.fda.gov/media/185526/download?attachment=
  6. ca5.uscourts.gov · Source 6 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
  7. ca5.uscourts.gov · Source 7 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  8. fda.gov · Source 8 ↗https://www.fda.gov/media/97347/download
  9. fda.gov · Source 9 ↗https://www.fda.gov/media/98973/download
  10. fda.gov · Source 10 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
  11. fda.gov · Source 11 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  12. federalregister.gov · Source 12 ↗https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
  13. hhs.gov · Source 13 ↗https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
  14. govinfo.gov · Source 14 ↗https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
  15. fda.gov · Source 15 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
  16. fda.gov · Source 16 ↗https://www.fda.gov/industry/fda-user-fee-programs/human-drug-compounding-outsourcing-facility-fees
  17. azbn.gov · Source 17 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
  18. accessdata.fda.gov · Source 18 ↗https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html
  19. fda.gov · Source 19 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  20. pharmacy.ca.gov · Source 20 ↗https://www.pharmacy.ca.gov/laws_regs/approved_regs.shtml
  21. pharmacy.ca.gov · Source 21 ↗https://pharmacy.ca.gov/online/faqs.shtml
  22. sapro.senate.ca.gov · Source 22 ↗https://sapro.senate.ca.gov/system/files/2026-08/hearing_results-8-13-26-suspense.pdf
  23. pages.usp.org · Source 23 ↗https://pages.usp.org/rs/711-SXF-172/images/USP_HQS_797_FAQs_December2023_V6__002.pdf?version=0
  24. telehealth.hhs.gov · Source 24 ↗https://telehealth.hhs.gov/licensure/licensing-across-state-lines
  25. fda.gov · Source 25 ↗https://www.fda.gov/media/194424/download
  26. fda.gov · Source 26 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  27. fda.gov · Source 27 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/title-ii-drug-quality-and-security-act
  28. fda.gov · Source 28 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-indulgence-aesthetics-723267-04012026
  29. accessdata.fda.gov · Source 29 ↗https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf
  30. fda.gov · Source 30 ↗https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
  31. cms.gov · Source 31 ↗https://www.cms.gov/files/document/status-update-bridge-demo-balance-model-part-d-cy2027-g-pdf.pdf
  32. cms.gov · Source 32 ↗https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications
  33. cms.gov · Source 33 ↗https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf
  34. cms.gov · Source 34 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
  35. cms.gov · Source 35 ↗https://www.cms.gov/priorities/innovation/innovation-models/balance
  36. fda.gov · Source 36 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  37. fda.gov · Source 37 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
  38. fda.gov · Source 38 ↗https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
  39. ftc.gov · Source 39 ↗https://www.ftc.gov/legal-library/browse/cases-proceedings/hims-hers-health-inc-ftc-v-timeline-item-2026-11-10
  40. ftc.gov · Source 40 ↗https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices
Section sources →